

**Tim Shannon, M.D.** *Venture Partner, Caanan Partners*



**“Venture Capital and the World of Biopharmaceutical Start-Ups”**

**June 21<sup>st</sup>**

Dr. Shannon has been a Venture Partner at Canaan Partners, a venture capital firm, since November 2009 and a General Partner since January 2015 where he is involved in the creation and growth of early stage biopharmaceutical companies. Dr. Shannon currently serves on the boards of directors of private companies Arvinas, Inc. (“Arvinas”), Ideaya Biosciences, Inc., NextCure, Inc., Spyryx Biosciences, all R&D focused biopharmaceutical companies. Prior to CuraGen, he held positions of increasing responsibility for Bayer AG’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. He previously served as a member of the board of directors of Civitas Therapeutics, Inc., which was acquired in October 2014 by Acorda Therapeutics, Inc., Novira Therapeutics, Inc., which was acquired by Johnson & Johnson in December 2015 and CytomX (CTMX, IPO 2015). Dr. Shannon served as assistant professor of the pulmonary and critical care division at Yale University School of Medicine and as an attending physician in pulmonary and critical care medicine at the West Haven V.A. Medical Center. Dr. Shannon received his post graduate medical training at the Beth Israel Hospital of Harvard Medical School and at Boston University. He earned his M.D. from the University of Connecticut and has a B.A. in chemistry from Amherst College.